Overcoming Immune Checkpoint Inhibitor Resistance in NSCLC: A Review of Emerging Therapeutic Strategies

Non-Small Cell Lung Cancer (NSCLC), Reviews /

60-85% of NSCLC patients develop secondary resistance to ICIs, creating critical unmet need requiring novel immunotherapy strategies.

Overcoming Immune Checkpoint Inhibitor Resistance in NSCLC: A Review of Emerging Therapeutic Strategies Read More »